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Heparan sulfate (HS) in the glomerular basement membrane (GBM) is important for regulation of the charge-dependent
permeability. Heparanase has been implicated in HS degradation in several proteinuric diseases. This study analyzed the role
of heparanase in HS degradation in Adriamycin nephropathy (AN), a model of chronic proteinuria-induced renal damage.
Expression of heparanase, HS, and the core protein of agrin (to which HS is attached) was determined on kidney sections from
rats with AN in different experiments. First, expression was examined in a model of unilateral AN in a time-course study at
6-wk intervals until week 30. Second, rats were treated with the hydroxyl radical scavenger dimethylthiourea (DMTU) during
bilateral AN induction. Finally, 6 wk after AN induction, rats were treated with angiotensin II receptor type 1 antagonist
(AT1A) or vehicle for 2 wk. Heparanase expression was increased in glomeruli of rats with AN, which correlated with HS
reduction at all time points and in all experiments. Treatment with DMTU prevented the increased heparanase expression, the
loss of GBM HS, and reduced albuminuria. Finally, treatment of established proteinuria with AT1A significantly reduced
heparanase expression and restored glomerular HS. In conclusion, an association between heparanase expression and
reduction of glomerular HS in AN was observed. The effects of DMTU suggest a role for reactive oxygen species in
upregulation of heparanase. Antiproteinuric treatment by AT1A decreased heparanase expression and restored HS expression.
These results suggest involvement of radicals and angiotensin II in the modulation of GBM permeability through HS and
heparanase expression.
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T he glomerular basement membrane (GBM) consists ofmany extracellular matrix proteins, including heparansulfate (HS) proteoglycans, mainly agrin. Loss of neg-
atively charged HS molecules results in an altered charge-
dependent permeability of the GBM (1). The importance of HS
in the charge-dependent permeability of the GBM has been
demonstrated in several studies. First, digestion of HS by hep-
aritinase resulted in increased permeability of the GBM for
ferritin and albumin (2,3). Second, injection of a specific mAb
against HS caused massive albuminuria in rats (4). Third, loss
of anionic HS has been reported in several human and exper-
imental glomerulopathies, which was inversely correlated with
the degree of proteinuria (5,6). It is suggested that proteinuria-
induced renal damage is associated with loss of glomerular HS
in diabetic and nondiabetic renal disease (7–9).
HS loss in proteinuric renal disease can be attributed to
several mechanisms (reviewed in reference [1]), such as depo-
lymerization of HS by reactive oxygen species (ROS), masking
of HS by nucleosome/Ig complexes, reduction of both HS
production and sulfation as a result of hyperglycemia, comple-
ment-mediated cleavage of HS, and proteolytic cleavage of the
HS attachment site on the core protein by enzymes.
Heparanase is an endo-(1,4)-d-glucuronidase that is in-
volved in the cleavage of HS and hence is associated with
extracellular matrix degradation and tissue remodeling (10–
13). A recent study in patients with diabetic nephropathy sug-
gested that loss of HS in the GBM is attributable to accelerated
HS degradation by increased heparanase expression (14). Stud-
ies in experimental renal diseases (passive Heymann nephritis,
puromycin aminonucleoside nephrosis, and anti-GBM nephri-
tis) suggest that heparanase also may be involved in nondia-
betic proteinuric disease (15–18).
In chronic proteinuric renal diseases, blockade of the renin-
angiotensin system (RAS) reduces proteinuria and thereby re-
duces progressive renal function loss. In Adriamycin nephrop-
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athy (AN), a model of chronic proteinuric renal damage (19),
we previously reported a decrease of HS expression, which was
caused partially by hydroxyl radicals (7). Furthermore, we
found that RAS blockade protects against loss of HS in estab-
lished AN (9). However, whether changes in heparanase may
be involved in the decrease of HS expression in AN and/or the
effects of RAS blockade is unknown. Therefore, in this study we
first determined the time course of heparanase and HS expres-
sion in relation to the development of proteinuria and renal
structural damage in AN. For this purpose, we used the uni-
lateral variant of the AN model to allow good resolution over
time. Next, the effect of scavenging of ROS during the period of
induction of AN on heparanase and HS expression and on
proteinuria was studied. Finally, we evaluated the potential of
antiproteinuric treatment with an angiotensin I receptor antag-
onist (AT1A) to restore the disbalance between heparanase and
HS in established AN with persistent proteinuria.
Materials and Methods
Animals and Experimental Design
Male Wistar rats were housed in a temperature-controlled room with
a 12-h light-dark cycle and with free access to food and water. Twenty-
four-hour urine samples were collected every 2 wk in metabolic cages,
with measurement of water and food intake. Surgical procedures took
place under isoflurane anesthesia in N2O/O2 (1:2). Systolic BP was
measured weekly by the tail-cuff method in conscious rats (20). At the
end of the study, the abdominal aorta was cannulated, a 2-ml blood
sample was taken, and kidneys were perfused in situ with saline and
removed. Proteinuria was measured on a BNII third-generation neph-
elometer (Dade Behring, Mannheim, Germany) by using a 20% trichlo-
roacetic acid solution. The Committees for Animal Experiments of the
University of Groningen and the Radboud University Nijmegen, The
Netherlands, approved all studies.
Experiment 1. Unilateral AN was induced by temporarily clip-
ping the left renal artery and vein through a midline abdominal incision
(20), followed by Adriamycin (1.5 mg/kg body wt) injection via the tail
vein. After 12 min, when Adriamycin had been cleared from the circu-
lation (19), the clamp was removed. For studying expression of hepara-
nase, HS and renal damage over time, eight rats (at each time point)
were killed at weeks 6, 12, 18, 24, and 30. In this experiment, the right
kidney—exposed to Adriamycin—was compared with the control
(nonexposed, left) kidney. Previously, we showed that the clipped left
kidney did not differ from healthy control kidneys, not even after 30 wk
(21).
Experiment 2. Bilateral AN was induced by intravenous injection
of 5 mg/kg body wt Adriamycin via the tail vein. One group of rats
(n  8) received an initial intraperitoneal injection of the hydroxyl
scavenger dimethylthiourea (DMTU; 500 mg/kg body wt; Sigma, St.
Louis, MO) 6 h before Adriamycin injection, followed by treatment
with DMTU (1.25 mg/kg body wt) twice a day for 7 d. The control
group (n  7) received saline instead of DMTU. Rats were killed 4 wk
after the injection of Adriamycin. Urine was collected at weeks 0 and 4
for determination of urinary albumin excretion.
Experiment 3. Bilateral AN was induced by intravenous injection
of Adriamycin (2 mg/kg body wt) via the tail vein. At week 6, a renal
biopsy was performed via a dorsolateral incision. After removal of a
part of the lower pole from the left kidney, gel foam (Spongostan;
Ferrosan, Copenhagen, Denmark) was applied for hemostasis. After
recovery, rats were treated with the angiotensin II type 1 receptor
antagonist (AT1A) L158,809 (150 mg/L drinking water; n  20) or
vehicle (n  10). In previous experiments, the biopsy did not affect the
course of renal damage (9,22). Treatment was continued until the rats
were killed at week 8. Eight healthy rats that were killed at week 6 were
used as time controls.
Immunofluorescence Staining
To determine heparanase, HS, and agrin core protein expression, we
performed indirect immunofluorescence staining on 2-m cryostat kidney
sections. Tissue sections were fixed in 100% acetone for 10 min at 4°C,
followed by 1 h of incubation of primary antibodies diluted in PBS that
contained 1% BSA and 0.01% sodium azide at room temperature. After
washing in PBS, the appropriate secondary antibodies were diluted in PBS
and incubated for 1 h at room temperature, with 5% normal rat serum and
10% normal goat serum. Specific primary and secondary antibodies that
were used are summarized in Table 1. Subsequently, the sections were
washed in PBS and embedded in Vectashield mounting medium H-1000
(Vector Laboratories, Burlingame, CA).
Table 1. Antibodies used for immunofluorescence
Antibody Specificity and Epitope Dilution Source Secondary Antibodya
HPA1 Rabbit anti-heparanase: 50-kD/8-kD
heterodimer
1:100 ProsPec-Tany Technogene,
Rehovet, Israel
Goat anti-rabbit IgG Alexa 594 or
488
JM403 Mouse anti-rat HS: N-unsubstituted
glucosamine unit
1:300 (4,41) Goat anti-mouse IgM Alexa 488
MI91 Hamster anti-agrin core protein: N-
terminus
1:800 (42) Goat anti-hamster IgG Cy3
OX7 Mouse anti-Thy1.1: Mesangium cells 1:300 PharMingen, San Diego, CA Goat anti-mouse IgG Alexa 488
G1D4 Mouse anti-synaptopodin: Podocyte
cytoskeleton
1:1 Progen Biotechnik,
Heidelberg, Germany
Goat anti-mouse IgG Alexa 488
300 Mouse anti–calbindin D-28k: Distal
convoluted tubuli
1:300 Swant, Bellinzona,
Switzerland
Goat anti-mouse IgG Alexa 488
AQP2 Guinea pig anti–aquaporin 2:
Collecting duct
1:300 Kindly provided by Dr. P.
Deen (43)
Goat anti-guinea pig IgG Alexa 488
C219 Mouse anti–P-glycoprotein: Proximal
tubuli
1:20 Abcam, Cambridge, UK Goat anti-mouse IgG Alexa 488
aSecondary Alexa antibodies were purchased from Invitrogen (Molecular Probes, Breda, The Netherlands) and were used in
a dilution of 1:200; Cy3-labeled antibody was obtained from Jackson ImmunoResearch Laboratories (Cambridgeshire, UK) and
used in a dilution of 1:800.
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For investigation of which glomerular cell type was responsible for
the expression of heparanase in AN, sections were double-stained with
anti-heparanase and (1) anti-agrin, to distinguish between the outside
of the GBM covered by podocytes and the inside with endothelial cells
lining the GBM; (2) anti-synaptopodin, which stains the cytoskeleton of
podocytes; and (3) anti-Thy1.1, which is a mesangial cell marker. For
investigation of in which tubular cell type heparanase was expressed,
double stainings were performed with anti-heparanase and (1) anti–
aquaporin 2, a marker for collecting ducts; (2) anti–calbindin D-28k, a
marker for distal convoluted tubuli; and (3) anti–P-glycoprotein, a
marker for proximal tubuli (summarized in Table 1). Confocal laser
scanning microscopy (Leica, Heidelberg, Germany) was used to eval-
uate the stainings.
Quantification of Immunofluorescence Staining and
Histochemistry
The kidney sections were randomly coded and evaluated by two
independent observers on a Zeiss Axioskop microscope (equipped with
an epi-illuminator). For agrin and HS expression, linearity of the GBM
was scored at an arbitrary scale of 0 to 10 (0  no staining, 1  10%
linear GBM staining, etc., with a maximum score of 10 for 100% stain-
ing). Heparanase expression was scored from 0 to 5 arbitrary units for
staining intensity. Expression was analyzed in 25 glomeruli per animal.
Focal glomerulosclerosis (FGS) was scored semiquantitatively on
periodic acid-Schiff–stained paraffin sections (4 m), as described pre-
viously (23). FGS lesions were defined as glomerular areas with mes-
angial expansion and adhesion formation simultaneously present in
one segment. Scoring was performed on a scale of 0 to 4 in 50 glomeruli
per kidney moving from outer to inner cortex. The FGS scores pre-
sented in Tables 2 and 3 are the median FGS scores per 50 glomeruli per
experimental animal group multiplied by 100 (score in arbitrary units
from 0 to 400).
Statistical Analyses
Data are expressed as median and 95% confidence intervals. Differ-
ences between groups were determined by Kruskal-Wallis and Mann-
Whitney U tests. Linear regression was performed to detect whether
proteinuria and heparanase and HS expression were associated. Anal-
yses were performed using SPSS version 12.0 (SPSS, Inc., Chicago, IL)
and GraphPad Prism, version 4.0 software (GraphPad Software, Inc.,
San Diego, CA). Statistical significance was regarded at P  0.05.
Results
Clinical and Morphologic Data
Data on proteinuria and BP for the time-course study (exper-
iment 1) and the intervention study (experiment 3) are shown
in Tables 2 and 3, respectively. In unilateral AN, proteinuria
was increased at all time points and BP was normal. The score
for FGS was increased in the Adriamycin-exposed kidney com-
pared with the nonexposed control kidney and progressed over
time. When rats were treated with DMTU before induction of
bilateral AN, albuminuria at week 4 was lower compared with
that in saline-treated rats with AN (255 [185 to 276] versus 353
[274 to 436] mg/24 h; P  0.05). In the intervention study at
week 6 (before treatment with AT1A started), proteinuria was
markedly increased compared with healthy controls. Treatment
during 2 wk with AT1A reduced proteinuria and BP. The score
for FGS did not change during the 2 wk of treatment. In the
vehicle-treated group, proteinuria and BP and FGS score re-
mained stable.
Heparanase Overexpression Is Associated with Reduced HS
Expression in AN: Time Course
Glomerular HS and heparanase expression in the exposed
and nonexposed kidney, assessed by indirect immunofluores-
cence staining on cryostat sections, is shown in Figure 1. HS
showed a nice linear staining along the GBM in control kidneys
(Figure 1A). However, in Adriamycin-exposed kidneys, the
intensity of HS expression in the GBM was reduced, whereas
agrin expression remained unaltered (Figure 1B). Semiquanti-
tative analysis revealed that HS was significantly reduced in
Adriamycin-exposed kidneys at all time points without
changes over time, whereas agrin core protein expression did
not differ between control and Adriamycin-exposed kidneys
(Figure 2, A and B). Heparanase expression was markedly
increased in all Adriamycin-exposed kidneys (Figure 1D) as
compared with the control kidneys (Figure 1C), which was
confirmed by semiquantitative analysis. Heparanase expres-
sion was increased significantly at all time points (Figure 2C)
without changes over time. The reduction in glomerular HS
expression significantly correlated with an increase in hepara-
nase expression (R2  0.34, P  0.001; Figure 2D). Taken
together, these results indicate that increased heparanase ex-
pression and loss of glomerular HS are early events in the time
course of the Adriamycin-induced nephrotic syndrome.
DMTU Reduces the Early Effect of Adriamycin on HS and
Heparanase Expression
Because HS reduction in AN has been attributed to a depo-
lymerization of HS by ROS (7), we studied whether the in-
creased heparanase expression could be attributed to ROS by
treating rats with the hydroxyl radical scavenger DMTU during
disease induction by Adriamycin and the first week afterward.
Table 2. Characteristics of the time-course study in unilateral AN (experiment 1)a
Week 6 Week 12 Week 18 Week 24 Week 30
Uprot (mg/24 h) 122 (72 to 367) 191 (142 to 414) 237 (183 to 395) 221 (70 to 351) 265 (159 to 459)
SBP (mmHg) 140 (112 to 146) 140 (122 to 166) 140 (122 to 156) 163 (120 to 183) 152 (138 to 190)
FGS control 0 (0 to 16) 2 (0 to 12) 8 (2 to 24) 19 (2 to 54) 24 (2 to 50)
FGS ADR 3 (0 to 16)b 20 (0 to 48)b 43 (10 to 78)b 45 (6 to 96)b 67 (38 to 148)b
aADR, Adriamycin-exposed kidney; AN, Adriamycin nephropathy; FGS, focal glomerulosclerosis; SBP, systolic BP; Uprot,
proteinuria.
bP  0.05 versus control (nonexposed kidneys).
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When the rats were killed, 3 wk later, a loss of HS was observed
in the saline-treated rats that was partly prevented by the
treatment with DMTU (Figure 3A), whereas expression of agrin
was comparable in both groups (data not shown), which is in
line with previous experiments (7). It is interesting that the
glomerular heparanase expression in AN rats that were treated
with the ROS scavenger DMTU was significantly lower com-
pared with that in saline-treated AN rat (Figure 3B).
Reduction of Heparanase and Increase in HS Expression
after Treatment with AT1A
Next, we investigated whether, in established proteinuria,
antiproteinuric treatment by AT1A can reduce glomerular
heparanase expression along with restoration of HS expression
in the GBM. HS (proteoglycans) and heparanase expression
was determined in bilateral AN, before (week 6) and after 2 wk
of treatment with AT1A or vehicle (week 8). Glomerular HS
expression was decreased in all Adriamycin-exposed animals
at week 6, and heparanase expression was markedly increased,
which was comparable with the results observed in the unilat-
eral model of AN (Figure 4). Treatment with AT1A significantly
increased glomerular HS expression compared with the vehi-
cle-treated animals (Figure 4A), which was, interestingly, ac-
companied by a significant reduction in heparanase (Figure
4B). However, AT1 receptor blockade did not completely re-
store HS expression to normal levels as observed in the healthy
controls. For the individual Adriamycin animals (vehicle and
AT1A at weeks 6 and 8), the reduction in glomerular HS
expression was significantly correlated with increased hepara-
nase expression (R2  0.63, P  0.001; Figure 4C).
Heparanase Expression in Glomeruli and Tubuli
Heparanase expression in AN is located at the outer side of
the GBM and is minimally expressed within the capillary loops
(Figure 5, A through C). Co-localization with synaptopodin
confirms that heparanase is expressed by the podocytes and not
by mesangium cells, because no co-localization with anti-
Thy1.1 could be observed.
Heparanase is expressed in tubuli of both normal and dis-
eased animals. Tubular HS and heparanase expression was not
altered by either Adriamycin injection or AT1A treatment com-
pared with controls. Using specific tubular markers, we ob-
served that heparanase is expressed mainly in proximal tubuli.
No expression was found in the distal convoluted tubuli or
collecting ducts (Figure 5, D through F).
Discussion
Our data demonstrate that glomerular heparanase expres-
sion is increased in Adriamycin-induced nephropathy and as-
sociated with a decreased HS expression in the GBM. These
changes occur early after disease induction and remain stable
during follow-up, whereas renal structural damage progresses.
We previously found ROS to induce loss of glomerular HS (7);
our data show that treatment with the ROS scavenger DMTU
reduces heparanase expression compared with saline-treated
Adriamycin rats, with subsequently a better preservation of
glomerular HS expression and amelioration of albuminuria.
Finally, glomerular heparanase expression in established AN
was reversible by antiproteinuric treatment with RAS blockade,
along with an increased glomerular HS expression.
In a previous study, we reported that by treatment with a
ROS scavenger, HS expression was not completely restored and
albuminuria was not completely prevented in AN (7), suggest-
ing that additional mechanisms are involved in the reduction of
HS in this model. Our study demonstrates that heparanase
expression is increased in AN and correlated with the loss of
HS in the GBM, suggesting that heparanase may play an im-
portant role in HS reduction. The increased expression of
heparanase in AN is in line with the findings in puromycin
aminonucleoside nephrosis, passive Heymann nephritis, and
anti-GBM nephritis (15–18). The loss of glomerular HS also is in
accordance with previous studies in proteinuric renal disease
(7–9). Our data on a consistent association between HS and
heparanase suggest that heparanase is an important factor in-
volved in the breakdown of HS and thereby in the development
of proteinuria. The pathogenic potential for heparanase in pro-
teinuria is supported by a recent study showing that inhibition
of heparanase prevented both proteinuria and loss of HS in
passive Heymann nephritis (16). Moreover, heparin and hepa-
rin derivatives that inhibit heparanase have been shown to
exert antiproteinuric effects in diabetic nephropathy, further
supporting the impact of heparanase (24).
As mentioned before, ROS have already been demonstrated
to be involved in the loss of HS in AN, which we explained by
ROS-mediated depolymerization of HS (7). In this study, treat-
Table 3. Characteristics of the intervention study in bilateral AN (experiment 3)a
Vehicle AT1 Antagonist Controls
Week 6 Week 8 Week 6 Week 8 Week 6
Uprot (mg/24 h) 777 (254 to 883)b 697 (257 to 834)b 680 (250 to 904)b 245 (33 to 638)c,d 13 (11 to 17)
SBP (mmHg) 149 (140 to 171) 144 (97 to 156) 143 (124 to 164) 113 (60 to 148)c,d 140 (131 to 161)
FGS score 20 (0 to 30)b 30 (2 to 52) 12 (0 to 97)b 16 (2 to 87) 0 (0 to 2)
aAT1, angiotensin II receptor type 1.
bP  0.05 versus controls.
cP  0.05 versus week 6.
dP  0.05 versus vehicle.
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ment of AN with DMTU prevented the increase in heparanase
expression and the loss of HS in the GBM. Whether ROS
production in this model is persistent seems unlikely, because
treatment with DMTU (6 h before and for only 1 wk after
Adriamycin administration) partially prevents proteinuria, loss
of HS, and heparanase overexpression at later stages.
Treatment with an angiotensin-converting enzyme (ACE) in-
hibitor or AT1A ameliorates proteinuria in both human and ex-
perimental renal diseases, including AN, and provides renopro-
tection (21,25–30). Antiproteinuric treatment with AT1A in this
study led to a partially restored glomerular HS expression. This
effect of AT1A on HS expression in AN is comparable with the
effect of ACE inhibition that preserved glomerular HS expression
in rats with AN (9). Along with the restored HS expression after
treatment with AT1A, we observed a markedly reduced glomer-
ular heparanase expression. In vitro experiments show that angio-
tensin II reduces HS expression in the extracellular matrix of
human podocytes, raising the possibility of a direct effect (31). No
data on intrarenal angiotensin II are available in AN; however, we
have reported elevated intrarenal activity of ACE in AN, consis-
tent with a local activation of RAS (32).
We used three different approaches to study the expression
of glomerular heparanase and HS in AN. The first was a uni-
lateral model with a relatively low (1.5 mg/kg body wt) Adria-
mycin dosage to allow good resolution over time. In the second
study, the acute bilateral AN model (5 mg/kg body wt) with
DMTU treatment was used with short-term follow-up. Finally,
in the chronic bilateral AN model with AT1 intervention, we
used 2 mg/kg body wt. Despite variations in the induction and
severity of the model, the observed correlation between HS and
heparanase was present consistently.
Figure 1. Heparan sulfate (HS; proteoglycans) and heparanase
expression in Adriamycin nephropathy (AN) and control kid-
neys (indirect immunofluorescence staining). (A) JM403 stain-
ing for HS and MI91 staining for agrin core protein in a control
kidney; a nice linear staining of the glomerular basement mem-
brane (GBM) is observed for both HS and agrin. (B) HS and
agrin staining in an Adriamycin-exposed kidney: Glomerular
HS staining is decreased, whereas agrin staining remains linear.
(C) HS and heparanase staining in a control kidney: Hepara-
nase is present in the tubuli but absent in the glomerulus. (D)
HS and heparanase expression in an Adriamycin-exposed kid-
ney: A glomerulus with reduced HS expression and increased
heparanase expression. Magnification, 40.
Figure 2. Semiquantitative analysis of glomerular HS, agrin, and
heparanase expression in arbitrary units (A.U.) at different time
points in unilateral AN (experiment 1). (A) HS expression in the
GBM was significantly decreased in AN at all time points. (B)
Agrin core protein expression did not differ between Adriamycin-
exposed and control kidneys. (C) Glomerular heparanase expres-
sion was upregulated in AN at all time points. (D) Correlation
between HS staining and heparanase expression in unilateral AN.
Open symbols indicate score of nonexposed kidneys; filled sym-
bols indicate score of Adriamycin-exposed kidneys. *P  0.05.
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The changes in glomerular heparanase expression in the
Adriamycin model and its reversibility by ROS scavenging or
RAS blockade observed here theoretically could be due to
different factors, namely (1) ROS, (2) angiotensin II, and/or (3)
proteinuria. A single intrarenal administration of Adriamycin
leads to a chain of reactions. Generation of ROS leads to injury
of the podocytes, resulting in persistent proteinuria and in-
creased production of (local) angiotensin II. All three elements
(ROS, angiotensin II, and proteinuria), in our opinion, could be
sequentially responsible for the persistence of heparanase over-
expression. Although the generation of ROS can be induced by
angiotensin II (33–35), ROS also are thought to be induced by
Adriamycin per se. The beneficial effects of DMTU treatment
during the induction phase of AN support a role for ROS in the
induction of changed charge-selective properties of the GBM,
as a result of both a direct effect of ROS on HS and ROS-
induced heparanase expression. The effects of RAS blockade,
showing reversibility of heparanase upregulation in established
nephropathy, support a role for angiotensin II in heparanase
expression. As to proteinuria, the time course study with early
changes in heparanase and HS expression, which were stable
during long-term follow-up despite prolonged exposure to pro-
teinuria, suggests that increased heparanase and decreased HS
expression are causal to proteinuria rather than a consequence.
Furthermore, in a model of protein-overload nephropathy (36),
we could not demonstrate a reduction in HS or an increase in
heparanase expression (data not shown).
Our results suggest that both ROS and RAS are involved in
upregulation of heparanase expression. Several studies have dem-
onstrated that there is a link between ROS and RAS signaling.
Angiotensin II has been shown to induce ROS production,
whereas ROSmediates several effects of angiotensin II, such as on
protein synthesis, cell hypertrophy, and vascular endothelial
growth factor production. Scavengers of ROS ameliorate angio-
tensin II–induced or angiotensin II–mediated effects, whereas
Figure 3. Effect of treatment with the hydroxyl radical scaven-
ger dimethylthiourea (DMTU) before disease induction by
Adriamycin and the first week afterward (experiment 2). (A)
Decrease of HS expression in AN could be partly prevented by
treatment with DMTU. (B) Heparanase expression was signif-
icantly lower after treatment with DMTU. *P  0.05.
Figure 4. Effects of treatment with angiotensin type I receptor
antagonist (AT1A) or vehicle (VEH) on heparanase and HS
expression in bilateral AN (Experiment 3) compared with
healthy control rats at week 6. Indirect immunofluorescence
double staining was performed on kidney biopsies before
(week 6) and after treatment (week 8). (A) Glomerular HS
expression was reduced before treatment but restored after 2
wk of treatment with AT1A. Treatment with VEH did not
restore HS expression. (B) After 2 wk of treatment with AT1A,
heparanase expression decreased, and it did not change with
VEH treatment. (C) Correlation between HS staining and
heparanase expression in bilateral AN. *P  0.05.
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ACE inhibition or angiotensin II receptor blockade were able to
reverse oxidative stress (37–40). Further studies would be needed
to address the possible interactions between ROS and RAS in
regulation of heparanase expression in AN.
Conclusion
Heparanase plays an important role in the loss of HS in AN.
Heparanase expression is increased early in the time course of
AN and shows a clear association with the loss of HS in the
GBM and proteinuria, suggesting that heparanase is an impor-
tant mediator of loss of glomerular HS and development of
proteinuria in AN. Scavenging of ROS prevented upregulation
of heparanase and loss of HS. In addition to direct ROS-
mediated depolymerization of HS, which we have shown pre-
viously in vitro, ROS indirectly may contribute to the HS loss in
AN by upregulation of heparanase expression. It is feasible that
in AN, both direct and indirect ROS-mediated mechanisms are
operative. Reduction of heparanase and the subsequent resto-
ration of glomerular HS contribute to the beneficial effects of
RAS blockade. Our results suggest that both ROS and RAS play
a role in heparanase induction and in the breakdown of HS in
AN. However, the interplay between ROS and RAS in the
induction of heparanase requires further investigation.
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